Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Regains Compliance With Nasdaq Listing Requirements

NEW YORK (GenomeWeb) – WaferGen Bio-systems announced that its shares have regained compliance for listing on the Nasdaq.

On Dec. 13, the Fremont, California-based firm received a letter from the market's Listing Qualifications Department acknowledging that the closing bid price of its common stock had been $1.00 or more for ten consecutive business days as of Dec. 12.

This follows a 1-for-5 reverse stock split the company effected on Nov. 28 in a bid to boost the shares and satisfy the minimum bid price requirement for continued listing. The firm is set to merge with Takara Bio USA in a deal that will be based on consolidated fiscal year 2016 revenues, rather than share price.

In morning trading on the Nasdaq, shares of WaferGen were up almost 2 percent to $4.88.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.